Allison Petrilla

Allison Petrilla works closely with life sciences clients to design observational research studies, health economic evaluations, and market landscape assessments.

Allison has particular expertise in retrospective database analysis in both US and ex-US markets, and her work has been published across a wide range of therapeutic areas.

Prior to joining Avalere, Allison was a director of HEOR at IMS Health, focusing on retrospective study design and economic modeling for life sciences clients. She was also a health services researcher for the National Hospice and Palliative Care Organization and an HEOR consultant with ValueMedics Research.

She received an MPH with a concentration in health information systems from the George Washington University School of Public Health & Health Services in Washington, DC.

Authored Content

The COVID-19 pandemic has brought renewed attention and urgency to mitigating access barriers to recommended vaccines.

Avalere experts examined the changing oncology landscape amid the COVID-19 pandemic.

On August 25, “Calcimimetic Use in Dialysis-Dependent Medicare Fee-for-Service Beneficiaries and Implications for Bundled Payment” was published in Kidney 360. The article featured research and analytics conducted by Avalere experts.

Avalere analysis finds Medicare incurred $106.4 billion in 2016–2018 treating diseases potentially preventable with inline vaccines and select pipeline vaccine candidates. Those diseases also resulted in beneficiary costs of approximately $9.6 billion during the same time period.

In this third episode, Sam Ferguson, a consultant in Avalere’s Market Access practice, along with Allison Petrilla, a managing director in Avalere’s Health Economics and Advanced Analytics practice, and Amy Schroeder, a senior consultant in Avalere’s Market Access practice, discuss how stakeholders are utilizing and translating real-world evidence (RWE) into value for oncology.

New Avalere analysis evaluates the trends in baseline patient characteristics among Medicare fee-for-service beneficiaries with stand-alone Part D coverage who initiated a direct oral anticoagulant during the period 2013–2017.

Avalere experts recently presented their research, “Comparison of Healthcare Utilization Among Managed Medicaid Individuals Diagnosed with Multiple Sclerosis Treated with Emergent vs. Established Disease-Modifying Therapy in the US.”

New Avalere research finds that health plan members enrolled in plans that cover abuse-deterrent formulations (ADFs) of opioids have a lower risk of opioid abuse (OA) and overdose (OD) and lower opioid abuse-related hospitalizations than people in plans that do not offer coverage of ADF opioids.